Gratzke, C., Özgüroğlu, M., Peer, A., Sendur, M. A. N., Retz, M., Goh, J. C., . . . Piulats, J. M. (2025). Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: The randomized, double-blind, phase III KEYNOTE-991 study.
Citación estilo ChicagoGratzke, Christian, et al. Pembrolizumab Plus Enzalutamide and Androgen Deprivation Therapy Versus Placebo Plus Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-sensitive Prostate Cancer: The Randomized, Double-blind, Phase III KEYNOTE-991 Study. 2025.
Cita MLAGratzke, Christian, et al. Pembrolizumab Plus Enzalutamide and Androgen Deprivation Therapy Versus Placebo Plus Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-sensitive Prostate Cancer: The Randomized, Double-blind, Phase III KEYNOTE-991 Study. 2025.